This study is testing a drug called efgartigimod alfa for adults who have experienced their first episode of optic neuritis (inflammation of the optic nerve). Researchers want to see if efgartigimod alfa, given as a shot under the skin, can help improve vision faster and better than a placebo (an inactive substance). All participants will also receive standard steroid treatment. The main goals are to see if it's practical to use efgartigimod alfa for optic neuritis and if a larger study would be worthwhile. They will also look at how much vision improves after one month. You would be eligible if you are an adult aged 18 or older with a new diagnosis of optic neuritis.

Study design

This is a pilot study, meaning it's a small-scale test, with 20 participants. It's a randomized, placebo-controlled study, so some participants will receive efgartigimod alfa and others will receive a placebo, but you won't know which one you're getting.

What's involved

You would have your vision and blood tested, answer questions about your vision, and receive injections on Day 0 and Day 3. You would have periodic visits over 6 months.

Compensation

Not stated in the trial record.

Follow-up

The study will measure changes in vision for one month after treatment. The overall study adherence and recruitment rates will be measured for two years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.